Trial Outcomes & Findings for Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (NCT NCT03430011)
NCT ID: NCT03430011
Last Updated: 2024-05-24
Results Overview
DLT is defined as adverse events (AEs) that occur within 21 days following JCARH125 infusion and meet any of the following criteria: * Treatment-emergent Grade ≥3 allergic reactions related to JCARH125; * Treatment-emergent Grade 3 seizures, regardless of attribution, that do not resolve to Grade ≤2 within 3 days in participants who have no evidence of central nervous system (CNS) involvement of Multiple Myeloma or other CNS pathology; * Treatment-emergent autoimmune toxicity Grade ≥3, regardless of attribution (excluding B-cell aplasia); * Treatment-emergent Grade 3 CRS that does not resolve to Grade ≤2 within 72 hours; * Any other treatment-emergent Grade 3 AE related to JCARH125 that does not resolve to Grade ≤2 within 7 days; * Any treatment-emergent Grade 4 AE related to JCARH125 that does not resolve to Grade ≤2 within 7 days; * Treatment-emergent Grade 4 Cytokine Release Syndrome of any duration; * Any treatment-emergent Grade 5 toxicity not due to the underlying malignancy
Recruitment status
COMPLETED
Study phase
PHASE1/PHASE2
Target enrollment
165 participants
Primary outcome timeframe
From day 1 to day 22 following JCARH125 infusion (Up to 21 days)
Results posted on
2024-05-24
Participant Flow
Participant milestones
| Measure |
Phase 1 50 x 10^6 Cells
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Pre-Treatment
STARTED
|
15
|
30
|
27
|
22
|
22
|
14
|
25
|
10
|
|
Pre-Treatment
Received Lymphodepleting Chemotherapy (LDC)
|
15
|
30
|
26
|
21
|
20
|
14
|
24
|
10
|
|
Pre-Treatment
COMPLETED
|
14
|
30
|
26
|
21
|
20
|
14
|
24
|
10
|
|
Pre-Treatment
NOT COMPLETED
|
1
|
0
|
1
|
1
|
2
|
0
|
1
|
0
|
|
JCARH125 Treatment
STARTED
|
14
|
30
|
26
|
21
|
20
|
14
|
24
|
10
|
|
JCARH125 Treatment
COMPLETED
|
8
|
9
|
7
|
6
|
9
|
6
|
11
|
3
|
|
JCARH125 Treatment
NOT COMPLETED
|
6
|
21
|
19
|
15
|
11
|
8
|
13
|
7
|
Reasons for withdrawal
| Measure |
Phase 1 50 x 10^6 Cells
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Pre-Treatment
Death
|
1
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
|
Pre-Treatment
Screen Fail
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
Pre-Treatment
No JCARH125 - disease related complications
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
Pre-Treatment
Participant not eligible - other reasons
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
JCARH125 Treatment
Withdrawal by Subject
|
1
|
1
|
5
|
5
|
3
|
4
|
5
|
3
|
|
JCARH125 Treatment
Lost to Follow-up
|
0
|
1
|
0
|
0
|
1
|
0
|
1
|
0
|
|
JCARH125 Treatment
Death
|
4
|
19
|
10
|
8
|
5
|
3
|
4
|
2
|
|
JCARH125 Treatment
Other reasons
|
1
|
0
|
4
|
2
|
2
|
1
|
3
|
2
|
Baseline Characteristics
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Baseline characteristics by cohort
| Measure |
Phase 1 50 x 10^6 Cells
n=15 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=30 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
n=27 Participants
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
n=22 Participants
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
n=22 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
n=14 Participants
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
n=25 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
n=10 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
Total
n=165 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
12 Participants
n=5 Participants
|
19 Participants
n=7 Participants
|
16 Participants
n=5 Participants
|
15 Participants
n=4 Participants
|
14 Participants
n=21 Participants
|
9 Participants
n=10 Participants
|
17 Participants
n=115 Participants
|
5 Participants
n=6 Participants
|
107 Participants
n=6 Participants
|
|
Age, Categorical
>=65 years
|
3 Participants
n=5 Participants
|
11 Participants
n=7 Participants
|
11 Participants
n=5 Participants
|
7 Participants
n=4 Participants
|
8 Participants
n=21 Participants
|
5 Participants
n=10 Participants
|
8 Participants
n=115 Participants
|
5 Participants
n=6 Participants
|
58 Participants
n=6 Participants
|
|
Sex: Female, Male
Female
|
5 Participants
n=5 Participants
|
13 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
9 Participants
n=4 Participants
|
10 Participants
n=21 Participants
|
7 Participants
n=10 Participants
|
8 Participants
n=115 Participants
|
6 Participants
n=6 Participants
|
68 Participants
n=6 Participants
|
|
Sex: Female, Male
Male
|
10 Participants
n=5 Participants
|
17 Participants
n=7 Participants
|
17 Participants
n=5 Participants
|
13 Participants
n=4 Participants
|
12 Participants
n=21 Participants
|
7 Participants
n=10 Participants
|
17 Participants
n=115 Participants
|
4 Participants
n=6 Participants
|
97 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
1 Participants
n=10 Participants
|
1 Participants
n=115 Participants
|
0 Participants
n=6 Participants
|
12 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
13 Participants
n=5 Participants
|
25 Participants
n=7 Participants
|
25 Participants
n=5 Participants
|
19 Participants
n=4 Participants
|
20 Participants
n=21 Participants
|
12 Participants
n=10 Participants
|
24 Participants
n=115 Participants
|
7 Participants
n=6 Participants
|
145 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
3 Participants
n=6 Participants
|
8 Participants
n=6 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=10 Participants
|
1 Participants
n=115 Participants
|
2 Participants
n=6 Participants
|
8 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Black or African American
|
4 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
2 Participants
n=10 Participants
|
2 Participants
n=115 Participants
|
1 Participants
n=6 Participants
|
17 Participants
n=6 Participants
|
|
Race (NIH/OMB)
White
|
9 Participants
n=5 Participants
|
22 Participants
n=7 Participants
|
23 Participants
n=5 Participants
|
16 Participants
n=4 Participants
|
16 Participants
n=21 Participants
|
9 Participants
n=10 Participants
|
20 Participants
n=115 Participants
|
4 Participants
n=6 Participants
|
119 Participants
n=6 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
2 Participants
n=10 Participants
|
2 Participants
n=115 Participants
|
3 Participants
n=6 Participants
|
21 Participants
n=6 Participants
|
PRIMARY outcome
Timeframe: From day 1 to day 22 following JCARH125 infusion (Up to 21 days)Population: All participants who have either experienced a DLT or were followed for the full DLT evaluation period in phase 1
DLT is defined as adverse events (AEs) that occur within 21 days following JCARH125 infusion and meet any of the following criteria: * Treatment-emergent Grade ≥3 allergic reactions related to JCARH125; * Treatment-emergent Grade 3 seizures, regardless of attribution, that do not resolve to Grade ≤2 within 3 days in participants who have no evidence of central nervous system (CNS) involvement of Multiple Myeloma or other CNS pathology; * Treatment-emergent autoimmune toxicity Grade ≥3, regardless of attribution (excluding B-cell aplasia); * Treatment-emergent Grade 3 CRS that does not resolve to Grade ≤2 within 72 hours; * Any other treatment-emergent Grade 3 AE related to JCARH125 that does not resolve to Grade ≤2 within 7 days; * Any treatment-emergent Grade 4 AE related to JCARH125 that does not resolve to Grade ≤2 within 7 days; * Treatment-emergent Grade 4 Cytokine Release Syndrome of any duration; * Any treatment-emergent Grade 5 toxicity not due to the underlying malignancy
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=15 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=30 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
n=27 Participants
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
n=22 Participants
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
n=22 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Dose-Limiting Toxicity (DLT) in Phase 1
|
0 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
1 Participants
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: From the time of JCARH125 infusion to 90 days following the infusion (Up to 90 days)Population: All participants who received at least one infusion of JCARH125 (and at least one dose of anakinra as prophylactic intervention for phase 1 Anakinra) in phase 1 and in phase 1 Anakinra
TEAE is defined as an AE that starts any time from initiation of JCARH125 administration through and including 90 days following the JCARH125 infusion graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Any AE occurring after the initiation of another anticancer treatment will not be considered a TEAE. Grade 3=Severe; Grade 4=Life-threatening; and Grade 5=death.
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=14 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=30 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
n=26 Participants
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
n=21 Participants
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
n=20 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
n=14 Participants
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity in Phase 1 and Phase 1 Anakinra
TEAE
|
14 Participants
|
30 Participants
|
26 Participants
|
21 Participants
|
20 Participants
|
14 Participants
|
—
|
—
|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity in Phase 1 and Phase 1 Anakinra
Grade 3-5 TEAE
|
14 Participants
|
30 Participants
|
25 Participants
|
21 Participants
|
20 Participants
|
13 Participants
|
—
|
—
|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity in Phase 1 and Phase 1 Anakinra
Grade 5 TEAE
|
0 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity in Phase 1 and Phase 1 Anakinra
JCARH125-Related TEAE
|
12 Participants
|
26 Participants
|
25 Participants
|
21 Participants
|
20 Participants
|
14 Participants
|
—
|
—
|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity in Phase 1 and Phase 1 Anakinra
JCARH125-Related Grade 3-5 TEAE
|
5 Participants
|
10 Participants
|
15 Participants
|
16 Participants
|
16 Participants
|
7 Participants
|
—
|
—
|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity in Phase 1 and Phase 1 Anakinra
JCARH125-Related Grade 5 TEAE
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
PRIMARY outcome
Timeframe: From the time of JCARH125 infusion to 90 days following the infusion (Up to 90 days)Population: All participants who received at least one infusion of JCARH125 (and at least one dose of anakinra as prophylactic intervention for phase 1 Anakinra) in phase 1 and in phase 1 Anakinra
Clinically significant laboratory abnormalities are assessed by investigator and are reported as treatment-emergent adverse event (TEAE). TEAE is defined as an AE that starts any time from initiation of JCARH125 administration through and including 90 days following the JCARH125 infusion graded by Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Any AE occurring after the initiation of another anticancer treatment is not considered a TEAE. Grade 3=Severe; Grade 4=Life-threatening.
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=14 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=30 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
n=26 Participants
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
n=21 Participants
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
n=20 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
n=14 Participants
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Hypocalcaemia grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Hypoalbuminaemia grade 3
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Blood bilirubin increased grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Aspartate aminotransferase increased grade 3
|
0 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Aspartate aminotransferase increased grade 4
|
1 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Blood alkaline phosphatase increased grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Serum ferritin increased grade 3
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Neutropenia grade 3
|
4 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
3 Participants
|
1 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Neutropenia grade 4
|
10 Participants
|
28 Participants
|
22 Participants
|
20 Participants
|
17 Participants
|
10 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Anemia grade 3
|
9 Participants
|
19 Participants
|
16 Participants
|
11 Participants
|
13 Participants
|
10 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Thrombocytopenia grade 3
|
0 Participants
|
4 Participants
|
3 Participants
|
1 Participants
|
0 Participants
|
4 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Thrombocytopenia grade 4
|
4 Participants
|
15 Participants
|
11 Participants
|
12 Participants
|
11 Participants
|
5 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Leukopenia grade 3
|
0 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
3 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Leukopenia grade 4
|
4 Participants
|
8 Participants
|
12 Participants
|
7 Participants
|
3 Participants
|
4 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Lymphopenia grade 3
|
1 Participants
|
2 Participants
|
4 Participants
|
3 Participants
|
1 Participants
|
1 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Lymphopenia grade 4
|
0 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Febrile neutropenia grade 3
|
1 Participants
|
7 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Febrile neutropenia grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Haemolysis grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Hypofibrinogenaemia grade 3
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Hypophosphataemia grade 3
|
1 Participants
|
5 Participants
|
2 Participants
|
6 Participants
|
6 Participants
|
6 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Hypophosphataemia grade 4
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Hypocalcaemia grade 3
|
0 Participants
|
2 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Hypokalaemia grade 3
|
0 Participants
|
3 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Hyponatraemia grade 3
|
1 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Hypomagnesaemia grade 3
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Hyperglycaemia grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Hyperglycaemia grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Hypertriglyceridaemia grade 3
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Hypertriglyceridaemia grade 4
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 1 and Phase 1 Anakinra
Alanine aminotransferase increased grade 3
|
1 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
—
|
—
|
PRIMARY outcome
Timeframe: From first infusion to up to aproximately 61 monthsPopulation: All participants who received at least one infusion of JCARH125 (and at least one dose of anakinra as prophylactic intervention for phase 1 Anakinra), at dose level 600 x 10\^6 in phase 1 and in phase 1 Anakinra
Number of participants receiving prophylactic anakinra with grade ≥ 2 CRS relative to the number of participants treated at the recommended Phase 2 dose (RP2D) in the Phase 1 dose escalation portion of the trial with grade ≥ 2 CRS. CRS grade is defined by the most severe symptom (excluding fever). Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=20 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=14 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Number of Participants Receiving Prophylactic Anakinra With Grade ≥2 Cytokine Release Syndrome (CRS) in Phase 1 and Phase 1 Anakinra
|
11 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: From JCARH125 infusion to the first onset of Grade ≥2 CRS (Up to approximately 61 months)Population: All participants with grade ≥2 CRS who received at least one infusion of JCARH125 (and at least one dose of anakinra as prophylactic intervention for phase 1 Anakinra) at dose level 600 x 10\^6 in phase 1 and in phase 1 Anakinra
Time to first onset of Grade ≥2 CRS in participants receiving prophylactic anakinra relative to onset of Grade ≥ 2 CRS in participants treated at the RP2D(s) in the Phase 1 dose escalation portion of the trial. Time to onset is calculated from the latest JCARH125 infusion prior to the first onset of Grade \>= 2 CRS. CRS grade is defined by the most severe symptom (excluding fever). Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=11 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=4 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Time to Onset of Grade ≥2 Cytokine Release Syndrome (CRS) in Phase 1 and Phase 1 Anakinra
|
2.0 Days
Interval 1.0 to 3.0
|
2.0 Days
Interval 2.0 to 3.0
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Day 1, 2, 3Population: All participants who received at least one infusion of JCARH125 and at least one dose of anakinra as prophylactic intervention in phase 1 Anakinra
The number of participants receiving prophylactic anakinra with no CRS occurring on study days 1, 2, or 3. CRS grade is defined by the most severe symptom (excluding fever). Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=14 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Number of Participants Receiving Prophylactic Anakinra With no Cytokine Release Syndrome (CRS) Occurring on Days 1-3 in Phase 1 Anakinra
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: From the time of the JCARH125 infusion until disease progression, end of study, or the start of another anticancer therapy or stem cell transplant (Up to aproximately 61 months)Population: All participants who received conforming JCARH125 cell product at the recommended phase 2 dose and have measurable disease at the last disease assessment prior to receiving JCARH125 infusion in phase 2 and in phase 2a
ORR is defined as stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR), according to IMWG criteria. Participants without any reported disease response assessments will be considered non-responders. sCR=complete response plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR=negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow aspirates. When the only method to measure disease is by serum FLC levels, CR can be defined as a normal FLC ratio of 0.26 to 1.65; VGPR=serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein level plus urine M-protein level \< 100 mg/24 h; PR=≥ 50% reduction of serum M protein plus reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg/24 h
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=24 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=10 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Overall Response Rate (ORR) in Phase 2 and Phase 2a
|
91.7 Percent of participants
Interval 73.0 to 99.0
|
100.0 Percent of participants
Interval 69.2 to 100.0
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: From JCARH125 infusion through the day 29 visitPopulation: All participants who have the necessary PK measurements to provide interpretable results for this specific parameter of interest
Cmax is the maximal concentration of JCARH125 CAR T cells in the blood after its infusion as determined by quantitative polymerase chain reaction (qPCR) to detect the JCARH125 transgene.
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=14 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=30 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
n=26 Participants
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
n=21 Participants
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
n=20 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
n=14 Participants
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
n=24 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
n=10 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Maximum Observed Concentration (Cmax)
|
61037.57 Copies/UG
Geometric Coefficient of Variation 365.26
|
64705.82 Copies/UG
Geometric Coefficient of Variation 305.31
|
123460.33 Copies/UG
Geometric Coefficient of Variation 156.23
|
122228.99 Copies/UG
Geometric Coefficient of Variation 174.22
|
162706.00 Copies/UG
Geometric Coefficient of Variation 83.19
|
176233.64 Copies/UG
Geometric Coefficient of Variation 99.44
|
140331.08 Copies/UG
Geometric Coefficient of Variation 234.07
|
103009.98 Copies/UG
Geometric Coefficient of Variation 128.25
|
SECONDARY outcome
Timeframe: From JCARH125 infusion through the day 29 visitPopulation: All participants who have the necessary PK measurements to provide interpretable results for this specific parameter of interest
Tmax is the first study day the maximum observed concetration (Cmax) of JCARH125 CAR T cells in the blood is reached as determined by quantitative polymerase chain reaction (qPCR) to detect the JCARH125 transgene.
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=14 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=30 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
n=26 Participants
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
n=21 Participants
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
n=20 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
n=14 Participants
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
n=24 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
n=10 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Time to Maximum Observed Concentration (Tmax)
|
13.50 Day
Interval 7.0 to 28.0
|
11.00 Day
Interval 4.0 to 22.0
|
10.00 Day
Interval 3.0 to 21.0
|
10.00 Day
Interval 7.0 to 25.0
|
10.00 Day
Interval 3.0 to 23.0
|
13.50 Day
Interval 7.0 to 28.0
|
9.50 Day
Interval 4.0 to 22.0
|
14.50 Day
Interval 7.0 to 21.0
|
SECONDARY outcome
Timeframe: From JCARH125 infusion through 28 days after the infusionPopulation: All participants who have the necessary PK measurements to provide interpretable results for this specific parameter of interest
AUC (0-28) of JCARH125 CAR T cells in the blood as determined by quantitative polymerase chain reaction (qPCR) to detect the JCARH125 transgene.
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=13 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=30 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
n=26 Participants
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
n=20 Participants
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
n=20 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
n=13 Participants
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
n=23 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
n=10 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Area Under the Concertation-Time Curve (AUC) From Time Day 1 to Day 29 [AUC (0-28 Days)]
|
556080.86 Day*copies/UG
Geometric Coefficient of Variation 288.83
|
610142.64 Day*copies/UG
Geometric Coefficient of Variation 276.50
|
1307054.13 Day*copies/UG
Geometric Coefficient of Variation 159.86
|
1390556.32 Day*copies/UG
Geometric Coefficient of Variation 188.93
|
1956613.78 Day*copies/UG
Geometric Coefficient of Variation 80.39
|
2052280.38 Day*copies/UG
Geometric Coefficient of Variation 104.12
|
1427277.29 Day*copies/UG
Geometric Coefficient of Variation 226.53
|
1287032.03 Day*copies/UG
Geometric Coefficient of Variation 145.22
|
SECONDARY outcome
Timeframe: Day 29, 60, 90, 180, 270, 365, 545, 730Population: All participants who have the necessary PK measurements to provide interpretable results for the specific parameters of interest
Pharmacokinetics persistence of JCARH125 CAR T cells in the blood as determined by quantitative polymerase chain reaction (qPCR) over time to detect the JCARH125 transgene. Persistence is defined as a transgene count greater than or equal to the lower limit of detection (LLOD).
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=14 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=30 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
n=26 Participants
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
n=20 Participants
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
n=17 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
n=14 Participants
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
n=23 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
n=10 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Pharmacokinetics Persistence
Day 29
|
14 Participants
|
29 Participants
|
26 Participants
|
20 Participants
|
17 Participants
|
14 Participants
|
23 Participants
|
10 Participants
|
|
Number of Participants With Pharmacokinetics Persistence
Day 60
|
9 Participants
|
26 Participants
|
21 Participants
|
16 Participants
|
13 Participants
|
12 Participants
|
21 Participants
|
10 Participants
|
|
Number of Participants With Pharmacokinetics Persistence
Day 90
|
5 Participants
|
16 Participants
|
20 Participants
|
17 Participants
|
9 Participants
|
13 Participants
|
18 Participants
|
7 Participants
|
|
Number of Participants With Pharmacokinetics Persistence
Day 180
|
2 Participants
|
8 Participants
|
14 Participants
|
12 Participants
|
8 Participants
|
9 Participants
|
13 Participants
|
4 Participants
|
|
Number of Participants With Pharmacokinetics Persistence
Day 270
|
1 Participants
|
2 Participants
|
9 Participants
|
2 Participants
|
9 Participants
|
7 Participants
|
8 Participants
|
4 Participants
|
|
Number of Participants With Pharmacokinetics Persistence
Day 365
|
0 Participants
|
1 Participants
|
4 Participants
|
2 Participants
|
6 Participants
|
4 Participants
|
8 Participants
|
3 Participants
|
|
Number of Participants With Pharmacokinetics Persistence
Day 545
|
0 Participants
|
0 Participants
|
4 Participants
|
4 Participants
|
2 Participants
|
3 Participants
|
3 Participants
|
2 Participants
|
|
Number of Participants With Pharmacokinetics Persistence
Day 730
|
0 Participants
|
0 Participants
|
2 Participants
|
2 Participants
|
4 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: From the time of the JCARH125 infusion until disease progression, end of study, or the start of another anticancer therapy or stem cell transplant (Up to 61 approximately months)Population: All participants who received conforming JCARH125 cell product at the recommended phase 2 dose (and at least one dose of anakinra as prophylactic intervention for phase 1 Anakinra) and have measurable disease at the last disease assessment prior to receiving JCARH125 infusion in phase 1 and in phase 1 Anakinra
ORR is defined as stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR), according to IMWG criteria. Participants without any reported disease response assessments will be considered non-responders. sCR=complete response plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR=negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow aspirates. When the only method to measure disease is by serum FLC levels, CR can be defined as a normal FLC ratio of 0.26 to 1.65; VGPR=serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein level plus urine M-protein level \< 100 mg/24 h; PR=≥ 50% reduction of serum M protein plus reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg/24 h
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=14 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=30 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
n=26 Participants
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
n=20 Participants
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
n=20 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
n=14 Participants
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Overall Response Rate (ORR) in Phase 1 and Phase 1 Anakinra
|
78.6 Percent of participants
Interval 49.2 to 95.3
|
86.7 Percent of participants
Interval 69.3 to 96.2
|
96.2 Percent of participants
Interval 80.4 to 99.9
|
90.0 Percent of participants
Interval 68.3 to 98.8
|
100.0 Percent of participants
Interval 83.2 to 100.0
|
100.0 Percent of participants
Interval 76.8 to 100.0
|
—
|
—
|
SECONDARY outcome
Timeframe: From the time of the JCARH125 infusion until disease progression, end of study, or the start of another anticancer therapy or stem cell transplant (Up to aproximately 61 months)Population: All participants who received conforming JCARH125 cell product at the recommended phase 2 dose (and at least one dose of anakinra as prophylactic intervention for phase 1 Anakinra) and have measurable disease at the last disease assessment prior to receiving JCARH125 infusion
CRR is defined as stringent complete response (sCR) or complete response (CR), according to IMWG criteria. Participants without any reported disease response assessments will be considered non-responders. sCR=complete response plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR=negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow aspirates
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=14 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=30 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
n=26 Participants
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
n=20 Participants
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
n=20 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
n=14 Participants
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
n=24 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
n=10 Participants
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Complete Response Rate (CRR)
|
42.9 Percent of participants
Interval 17.7 to 71.1
|
33.3 Percent of participants
Interval 17.3 to 52.8
|
46.2 Percent of participants
Interval 26.6 to 66.6
|
45.0 Percent of participants
Interval 23.1 to 68.5
|
65.0 Percent of participants
Interval 40.8 to 84.6
|
35.7 Percent of participants
Interval 12.8 to 64.9
|
54.2 Percent of participants
Interval 32.8 to 74.4
|
40.0 Percent of participants
Interval 12.2 to 73.8
|
SECONDARY outcome
Timeframe: From first response to the date of progression or death due to any cause, whichever occurs first (Up to approixmately 61 months)Population: All participants with sCR, CR, VGPR, or PR who received conforming JCARH125 cell product at the recommended phase 2 dose and have measurable disease at the last disease assessment prior to receiving JCARH125 infusion in phase 2 and in phase 2a
DoR is defined as the time from first response (stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR)) to the earlier date of progressive disease or death due to any cause. sCR=complete response plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR=negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow aspirates; VGPR=serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein level plus urine M-protein level \< 100 mg/24 h; PR=≥ 50% reduction of serum M protein plus reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg/24 h. Progressive disease is defined as (1) Increase of ≥25% from lowest confirmed response; (2) Appearance of a new lesion(s); (3) ≥50% increase in circulating plasma cells.
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=22 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=10 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Duration of Response (DoR) in Phase 2 and 2a
|
18.2 Months
Interval 2.0 to 23.0
|
10.1 Months
Interval 1.0 to 23.0
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: From first response to the date of progression or death due to any cause, whichever occurs first (Up to approixmately 61 months)Population: All participants with sCR or CR who received conforming JCARH125 cell product at the recommended phase 2 dose and have measurable disease at the last disease assessment prior to receiving JCARH125 infusion in phase 2 and in phase 2a
DoCR is defined as the time from first response (stringent complete response (sCR), complete response (CR)) to the earlier date of progressive disease or death due to any cause. sCR=complete response plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR=negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow aspirates. Progressive disease is defined as (1) Increase of ≥25% from lowest confirmed response; (2) Appearance of a new lesion(s); (3) ≥50% increase in circulating plasma cells.
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=13 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=4 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Duration of Complete Response (DoCR) in Phase 2 and 2a
|
18.2 Months
Interval 0.0 to 23.0
|
10.8 Months
Interval 3.0 to 23.0
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: From the time of JCARH125 infusion to 90 days following the infusion (Up to 90 days)Population: All participants who received at least one infusion of JCARH125 in phase 2 and in phase 2a
TEAE is defined as an AE that starts any time from initiation of JCARH125 administration through and including 90 days following the JCARH125 infusion graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Any AE occurring after the initiation of another anticancer treatment will not be considered a TEAE. Grade 3=Severe; Grade 4=Life-threatening; and Grade 5=death.
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=24 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=10 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity in Phase 2 and Phase 2a
TEAE
|
24 Participants
|
10 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity in Phase 2 and Phase 2a
Grade 3-5 TEAE
|
23 Participants
|
9 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity in Phase 2 and Phase 2a
Grade 5 TEAE
|
2 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity in Phase 2 and Phase 2a
JCARH125-Related TEAE
|
23 Participants
|
8 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity in Phase 2 and Phase 2a
JCARH125-Related Grade 3-5 TEAE
|
16 Participants
|
7 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity in Phase 2 and Phase 2a
JCARH125-Related Grade 5 TEAE
|
1 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: From the time of JCARH125 infusion to 90 days following the infusion (Up to 90 days)Population: All participants who received at least one infusion of JCARH125 in phase 2 and in phase 2a
Clinically significant laboratory abnormalities are assessed by investigator and are reported as treatment-emergent adverse event (TEAE). TEAE is defined as an AE that starts any time from initiation of JCARH125 administration through and including 90 days following the JCARH125 infusion graded by Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Any AE occurring after the initiation of another anticancer treatment is not considered a TEAE. Grade 3=Severe; Grade 4=Life-threatening.
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=24 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=10 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Neutropenia grade 3
|
3 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Neutropenia grade 4
|
18 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Anemia grade 3
|
11 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Thrombocytopenia grade 3
|
3 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Thrombocytopenia grade 4
|
10 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Leukopenia grade 3
|
1 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Leukopenia grade 4
|
8 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Lymphopenia grade 3
|
1 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Lymphopenia grade 4
|
3 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Febrile neutropenia grade 3
|
1 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Hypophosphataemia grade 3
|
6 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Hypocalcaemia grade 3
|
3 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Hypocalcaemia grade 4
|
1 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Hypokalaemia grade 3
|
2 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Hyponatraemia grade 3
|
2 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Hyperglycaemia grade 3
|
2 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Hypertriglyceridaemia grade 3
|
3 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Lactic acidosis grade 3
|
1 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Alanine aminotransferase increased grade 4
|
1 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Aspartate aminotransferase increased grade 3
|
1 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Aspartate aminotransferase increased grade 4
|
1 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Blood fibrinogen decreased grade 3
|
1 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
Blood fibrinogen decreased grade 4
|
1 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities by Severity in Phase 2 and Phase 2a
CD4 lymphocytes decreased grade 3
|
1 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Form date of first infusion to the date of death due to any reason (Up to apprixamtely 61 months)Population: All participants who received conforming JCARH125 cell product at the recommended phase 2 dose and have measurable disease at the last disease assessment prior to receiving JCARH125 infusion in phase 2 and in phase 2a
OS is defined as the time from the JCARH125 infusion until death due to any cause.
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=24 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=10 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Overall Survival (OS) in Phase 2 and Phase 2a
|
NA Months
Interval 8.71 to
insufficient number of participants with events
|
NA Months
Interval 7.62 to
insufficient number of participants with events
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Form date of first infusion to the date of disease progression, or death, due to any reason (Up to approximately 61 months)Population: All participants who received conforming JCARH125 cell product at the recommended phase 2 dose and have measurable disease at the last disease assessment prior to receiving JCARH125 infusion in phase 2 and in phase 2a
PFS is defined as the time from JCARH125 infusion until the earliest date of disease progression or death from any cause. Progressive disease (PD) is defined as (1) Increase of ≥25% from lowest confirmed response in one or more of the following: Serum M-protein absolute increase ≥0.5 g/dL; Serum M-protein increase ≥1 g/dL, if the lowest M component was ≥5 g/dL; Urine M protein absolute increase ≥200 mg/24 h; the difference between involved and uninvolved FLC levels absolute increase \>10 mg/dL; Bone marrow plasma-cell percentage irrespective of baseline status absolute increase ≥10%. (2) Appearance of a new lesion(s), ≥50% increase from nadir in SPDd of \>1 lesion, or ≥50% increase in the longest diameter of a previous lesion \>1 cm in short axis. (3) ≥50% increase in circulating plasma cells (minimum of 200 cells μL) if this is the only measure of disease.
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=24 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=10 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Progression Free Survival (PFS) in Phase 2 and Phase 2a
|
14.75 Months
Interval 5.85 to 23.82
|
12.25 Months
Interval 3.25 to 17.94
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Form date of first infusion to the date of disease progression, or death, due to any reason (Up to approximately 61 months)Population: All participants with sCR, CR, VGPR, or PR who received conforming JCARH125 cell product at the recommended phase 2 dose and have measurable disease at the last disease assessment prior to receiving JCARH125 infusion in phase 2 and in phase 2a
TTR is defined from JCARH125 infusion to the first document of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). sCR=complete response plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR=negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow aspirates; VGPR=serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein level plus urine M-protein level \< 100 mg/24 h; PR=≥ 50% reduction of serum M protein plus reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg/24 h. Progressive disease is defined as (1) Increase of ≥25% from lowest confirmed response; (2) Appearance of a new lesion(s); (3) ≥50% increase in circulating plasma cells.
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=22 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=10 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Time to Response (TTR) in Phase 2 and Phase 2a
|
0.99 Months
Interval 0.9 to 12.5
|
0.97 Months
Interval 0.9 to 2.2
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Form date of first infusion to the date of disease progression, or death, due to any reason (Up to approximately 61 months)Population: All participants with sCR or CR who received conforming JCARH125 cell product at the recommended phase 2 dose and have measurable disease at the last disease assessment prior to receiving JCARH125 infusion in phase 2 and in phase 2a
TTCR is defined from JCARH125 infusion to the first document of stringent complete response (sCR) or complete response (CR). sCR=complete response plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR=negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow aspirates. Progressive disease is defined as (1) Increase of ≥25% from lowest confirmed response; (2) Appearance of a new lesion(s); (3) ≥50% increase in circulating plasma cells.
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=13 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=4 Participants
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Time to Complete Response (TTCR) in Phase 2 and Phase 2a
|
2.79 Months
Interval 1.0 to 15.2
|
1.41 Months
Interval 1.0 to 2.2
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline and visit 24 monthPopulation: All participants who received at least one infusion of JCARH125 with baseline and post-baseline assessment at the respective visit in phase 2 only as prespecified in the protocol
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures such as functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Subscale scores are transformed to 0 to 100 scale, with higher scores on functional scales indicating better function and higher score on symptom scales indicating worse symptoms. Baseline is defined as the last non-missing measurement prior to JCARH125 infusion.
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=4 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) in Phase 2
Global Health Status/QoL Month 24
|
-2.08 Score on a Scale
Standard Deviation 10.49
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) in Phase 2
Physical Functioning Month 24
|
-6.67 Score on a Scale
Standard Deviation 9.43
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) in Phase 2
Role Functioning Month 24
|
0.00 Score on a Scale
Standard Deviation 13.61
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) in Phase 2
Emotional Functioning Month 24
|
-6.25 Score on a Scale
Standard Deviation 7.98
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) in Phase 2
Cognitive Functioning Month 24
|
4.17 Score on a Scale
Standard Deviation 8.33
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) in Phase 2
Social Functioning Month 24
|
16.67 Score on a Scale
Standard Deviation 13.61
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) in Phase 2
Fatigue Month 24
|
5.56 Score on a Scale
Standard Deviation 6.42
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) in Phase 2
Pain Month 24
|
-4.17 Score on a Scale
Standard Deviation 8.33
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) in Phase 2
Nausea and Vomiting Month 24
|
4.17 Score on a Scale
Standard Deviation 8.33
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) in Phase 2
Dyspnea Month 24
|
-8.33 Score on a Scale
Standard Deviation 16.67
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) in Phase 2
Insomnia Month 24
|
0.00 Score on a Scale
Standard Deviation 27.22
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) in Phase 2
Appetite Loss Month 24
|
8.33 Score on a Scale
Standard Deviation 16.67
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) in Phase 2
Constipation Month 24
|
8.33 Score on a Scale
Standard Deviation 16.67
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) in Phase 2
Diarrhea Month 24
|
8.33 Score on a Scale
Standard Deviation 16.67
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) in Phase 2
Financial Difficulties Month 24
|
8.33 Score on a Scale
Standard Deviation 16.67
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline and visit 24 monthPopulation: All participants who received at least one infusion of JCARH125 with baseline and post-baseline assessment at the respective visit in phase 2 only as prespecified in the protocol
QLQ-MY20 includes 20 questions across four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology.
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=4 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (QLQ-MY20) in Phase 2
Disease Symptoms
|
0.00 Score on a Scale
Standard Deviation 0.00
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (QLQ-MY20) in Phase 2
Side Effects of Treatment
|
6.11 Score on a Scale
Standard Deviation 3.98
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (QLQ-MY20) in Phase 2
Future Perspectives
|
11.11 Score on a Scale
Standard Deviation 9.07
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (QLQ-MY20) in Phase 2
Body Image
|
16.67 Score on a Scale
Standard Deviation 33.33
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline and visit 24 monthPopulation: All participants who received at least one infusion of JCARH125 with baseline and post-baseline assessment at the respective visit in phase 2 only as prespecified in the protocol
EQ-5D-5L is a standardized measure of health status that consists of descriptive system and Visual Analogue scale VAS). The descriptive system comprises dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the dimensions are combined in a 5-digit number corresponding to response categories for successive dimensions using a scoring algorithm. The VAS system has endpoints labeled "the best health you can imagine" and "the worst health you can imagine." The scale is numbered from 0 to 100 with 0 corresponding to the worst imaginable health state and 100 corresponding to the best imaginable health state. A high score represents a better level of quality of life
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=4 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Change From Baseline (EQ-5D-5L) Index Score in Phase 2
Mobility Index Score
|
-0.3 Score on a scale
Standard Deviation 0.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline (EQ-5D-5L) Index Score in Phase 2
Self Care Index Score
|
0.0 Score on a scale
Standard Deviation 0.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline (EQ-5D-5L) Index Score in Phase 2
Activity Index Score
|
0.3 Score on a scale
Standard Deviation 0.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline (EQ-5D-5L) Index Score in Phase 2
Pain Index Score
|
0.0 Score on a scale
Standard Deviation 0.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline (EQ-5D-5L) Index Score in Phase 2
Anxiety Index Score
|
0.3 Score on a scale
Standard Deviation 1.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline (EQ-5D-5L) Index Score in Phase 2
Utility Index US Index Score
|
-0.0035 Score on a scale
Standard Deviation 0.1193
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: From JCARH125 infusion to up to approximately 61 monthsPopulation: All participants who received at least one infusion of JCARH125 with baseline and post-baseline assessment at the respective visit in phase 2 only as prespecified in the protocol
Total length of all intensive care unit (ICU) and non-ICU stays from JCARH125 Administration. ICU inpatient and non-ICU inpatient are not exclusive. Total length includes participants who had multiple hospitalization stays.
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=24 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Duration of Hospitalization From JCARH125 Administration in Phase 2
ICU inpatient
|
9.0 Days
Interval 3.0 to 32.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Duration of Hospitalization From JCARH125 Administration in Phase 2
non-ICU inpatient
|
11.0 Days
Interval 6.0 to 58.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: From JCARH125 infusion to up to approximately 61 monthsPopulation: All participants who received at least one infusion of JCARH125 with baseline and post-baseline assessment at the respective visit in phase 2 only as prespecified in the protocol
Number of participants with reasons for hospitalization from JCARH125 administration
Outcome measures
| Measure |
Phase 1 50 x 10^6 Cells
n=24 Participants
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Reasons for Hospitalization From JCARH125 Administration in Phase 2
Adverse Event
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Reasons for Hospitalization From JCARH125 Administration in Phase 2
Prophylaxis
|
21 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
Adverse Events
Phase 1 50 x 10^6 Cells
Serious events: 1 serious events
Other events: 14 other events
Deaths: 5 deaths
Phase 1 150 x 10^6 Cells
Serious events: 14 serious events
Other events: 30 other events
Deaths: 22 deaths
Phase 1 300 x 10^6 Cells
Serious events: 7 serious events
Other events: 26 other events
Deaths: 14 deaths
Phase 1 450 x 10^6 Cells
Serious events: 7 serious events
Other events: 21 other events
Deaths: 9 deaths
Phase 1 600 x 10^6 Cells
Serious events: 7 serious events
Other events: 20 other events
Deaths: 7 deaths
Phase 1 Anakinra 600 x 10^6 Cells
Serious events: 5 serious events
Other events: 14 other events
Deaths: 4 deaths
Phase 2 600 x 10^6 Cells
Serious events: 11 serious events
Other events: 24 other events
Deaths: 6 deaths
Phase 2a 600 x 10^6 Cells Anti-BCMA
Serious events: 1 serious events
Other events: 10 other events
Deaths: 2 deaths
Serious adverse events
| Measure |
Phase 1 50 x 10^6 Cells
n=14 participants at risk
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=30 participants at risk
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
n=26 participants at risk
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
n=21 participants at risk
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
n=20 participants at risk
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
n=14 participants at risk
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
n=24 participants at risk
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
n=10 participants at risk
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Blood and lymphatic system disorders
Disseminated intravascular coagulation
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Cardiac disorders
Left ventricular dysfunction
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Cardiac disorders
Pericardial effusion
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Cardiac disorders
Pericarditis
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Large intestinal obstruction
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Large intestine perforation
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
General disorders
General physical health deterioration
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
General disorders
Multiple organ dysfunction syndrome
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
General disorders
Pyrexia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Hepatobiliary disorders
Cholecystitis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Immune system disorders
Cytokine release syndrome
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
11.5%
3/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
9.5%
2/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
12.5%
3/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Immune system disorders
Haemophagocytic lymphohistiocytosis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
9.5%
2/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Appendicitis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Bacteraemia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
8.3%
2/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Bronchitis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
COVID-19
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Campylobacter infection
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Cellulitis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Cystitis viral
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Cytomegalovirus chorioretinitis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Cytomegalovirus infection
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Cytomegalovirus infection reactivation
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Escherichia bacteraemia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Klebsiella bacteraemia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Mastoiditis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Metapneumovirus infection
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Osteomyelitis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Otitis externa
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Parainfluenzae virus infection
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Pneumonia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Pneumonia aspiration
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Rhinovirus infection
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Sepsis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
9.5%
2/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Septic shock
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Skin infection
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Staphylococcal bacteraemia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Injury, poisoning and procedural complications
Transfusion reaction
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Tumour lysis syndrome
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Musculoskeletal and connective tissue disorders
Haemarthrosis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Musculoskeletal and connective tissue disorders
Myopathy
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant pleural effusion
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Nervous system disorders
Headache
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Nervous system disorders
Immune effector cell-associated neurotoxicity syndrome
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Nervous system disorders
Tremor
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Psychiatric disorders
Delirium
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Psychiatric disorders
Mental status changes
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
Other adverse events
| Measure |
Phase 1 50 x 10^6 Cells
n=14 participants at risk
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 150 x 10^6 Cells
n=30 participants at risk
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 300 x 10^6 Cells
n=26 participants at risk
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 450 x 10^6 Cells
n=21 participants at risk
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 600 x 10^6 Cells
n=20 participants at risk
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 1 Anakinra 600 x 10^6 Cells
n=14 participants at risk
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
|
Phase 2 600 x 10^6 Cells
n=24 participants at risk
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
|
Phase 2a 600 x 10^6 Cells Anti-BCMA
n=10 participants at risk
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
|
|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
64.3%
9/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
70.0%
21/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
65.4%
17/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
61.9%
13/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
75.0%
15/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
78.6%
11/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
75.0%
18/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
50.0%
5/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Blood and lymphatic system disorders
Coagulopathy
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
8.3%
2/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.0%
6/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Blood and lymphatic system disorders
Leukopenia
|
28.6%
4/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
26.7%
8/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
53.8%
14/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
42.9%
9/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
30.0%
6/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
35.7%
5/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
37.5%
9/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Blood and lymphatic system disorders
Lymphopenia
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
23.1%
6/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
3/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.8%
5/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Blood and lymphatic system disorders
Neutropenia
|
100.0%
14/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
96.7%
29/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
92.3%
24/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
100.0%
21/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
100.0%
20/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
78.6%
11/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
87.5%
21/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
70.0%
7/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
35.7%
5/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
70.0%
21/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
61.5%
16/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
66.7%
14/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
70.0%
14/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
64.3%
9/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
79.2%
19/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
40.0%
4/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Cardiac disorders
Bradycardia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
12.5%
3/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Cardiac disorders
Sinus tachycardia
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
9.5%
2/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
12.5%
3/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.0%
2/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Cardiac disorders
Ventricular tachycardia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Ear and labyrinth disorders
Hypoacusis
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Eye disorders
Dry eye
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Eye disorders
Photophobia
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Eye disorders
Swelling of eyelid
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Eye disorders
Vision blurred
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Anal incontinence
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Constipation
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
11.5%
3/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
28.6%
4/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
33.3%
8/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.0%
2/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Diarrhoea
|
42.9%
6/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
30.0%
9/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
19.2%
5/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
38.1%
8/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
35.0%
7/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
21.4%
3/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
25.0%
6/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
12.5%
3/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
12.5%
3/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Hyperaesthesia teeth
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Mouth cyst
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Nausea
|
42.9%
6/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
43.3%
13/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
19.2%
5/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
23.8%
5/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
15.0%
3/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
42.9%
6/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
33.3%
8/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.0%
2/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Vomiting
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.0%
6/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
11.5%
3/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
28.6%
6/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.8%
5/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
General disorders
Asthenia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
12.5%
3/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
General disorders
Catheter site dermatitis
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
General disorders
Chills
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
30.0%
3/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
General disorders
Fatigue
|
28.6%
4/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
30.0%
9/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
19.2%
5/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
28.6%
6/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
25.0%
5/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
35.7%
5/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
33.3%
8/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
30.0%
3/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
General disorders
Gait disturbance
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
General disorders
Malaise
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
8.3%
2/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
General disorders
Oedema peripheral
|
21.4%
3/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
26.7%
8/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
15.4%
4/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
28.6%
6/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
15.0%
3/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
16.7%
4/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.0%
2/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
General disorders
Pain
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
19.0%
4/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
12.5%
3/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
General disorders
Pyrexia
|
35.7%
5/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
16.7%
5/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
11.5%
3/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
9.5%
2/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
35.7%
5/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.8%
5/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
30.0%
3/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Hepatobiliary disorders
Hypertransaminasaemia
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Immune system disorders
Cytokine release syndrome
|
64.3%
9/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
70.0%
21/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
80.8%
21/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
90.5%
19/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
80.0%
16/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
78.6%
11/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
79.2%
19/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
70.0%
7/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Immune system disorders
Drug hypersensitivity
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Immune system disorders
Haemophagocytic lymphohistiocytosis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
9.5%
2/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Immune system disorders
Hypogammaglobulinaemia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
15.4%
4/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
19.0%
4/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
16.7%
4/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Cellulitis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Clostridium difficile colitis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Device related infection
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Oral candidiasis
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
15.4%
4/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Pneumonia
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Rhinitis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Rhinovirus infection
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
11.5%
3/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Upper respiratory tract infection
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
13.3%
4/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
3/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
8.3%
2/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Urinary tract infection
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Investigations
Alanine aminotransferase increased
|
21.4%
3/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
23.8%
5/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
30.0%
6/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
21.4%
3/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.8%
5/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Investigations
Aspartate aminotransferase increased
|
21.4%
3/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
16.7%
5/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
23.8%
5/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.0%
4/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
28.6%
4/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.8%
5/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Investigations
Blood alkaline phosphatase increased
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
3/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
16.7%
4/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
12.5%
3/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Investigations
Blood creatinine increased
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
21.4%
3/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Investigations
Blood fibrinogen decreased
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
16.7%
4/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Investigations
Blood lactate dehydrogenase increased
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
21.4%
3/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Investigations
Enterovirus test positive
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Investigations
Human rhinovirus test positive
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Investigations
International normalised ratio increased
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
15.0%
3/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
12.5%
3/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Investigations
Serum ferritin increased
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
13.3%
4/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
26.9%
7/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
28.6%
6/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
25.0%
5/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.8%
5/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Gout
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
9.5%
2/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
28.6%
4/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
16.7%
4/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Hyperphosphataemia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Hypertriglyceridaemia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
9.5%
2/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
16.7%
4/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Hypervolaemia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
8.3%
2/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
15.0%
3/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
42.9%
6/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
23.8%
5/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
25.0%
5/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
28.6%
4/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
25.0%
6/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
21.4%
3/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
46.7%
14/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
19.2%
5/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
28.6%
6/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
30.0%
6/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
28.6%
4/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
16.7%
4/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
30.0%
9/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
19.0%
4/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
25.0%
5/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
28.6%
4/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
12.5%
3/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
13.3%
4/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
3/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
42.9%
6/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
25.0%
6/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
30.0%
9/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
26.9%
7/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
33.3%
7/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
45.0%
9/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
50.0%
7/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
33.3%
8/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.0%
2/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Lactic acidosis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
8.3%
2/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Metabolic acidosis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
21.4%
3/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
8.3%
2/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
21.4%
3/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
23.3%
7/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
15.4%
4/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
3/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.0%
4/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
21.4%
3/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
16.7%
4/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
21.4%
3/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
16.7%
5/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
9.5%
2/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
8.3%
2/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Musculoskeletal and connective tissue disorders
Muscle twitching
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
13.3%
4/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
8.3%
2/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Nervous system disorders
Cognitive disorder
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Nervous system disorders
Dizziness
|
21.4%
3/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
15.4%
4/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
15.0%
3/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
12.5%
3/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Nervous system disorders
Dysaesthesia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Nervous system disorders
Headache
|
35.7%
5/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
26.7%
8/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
30.8%
8/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
38.1%
8/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.0%
4/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
28.6%
4/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
25.0%
6/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Nervous system disorders
Immune effector cell-associated neurotoxicity syndrome
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
11.5%
3/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Nervous system disorders
Lethargy
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Nervous system disorders
Presyncope
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Nervous system disorders
Sciatica
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Nervous system disorders
Tremor
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
11.5%
3/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
16.7%
4/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
9.5%
2/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
15.0%
3/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
16.7%
4/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Psychiatric disorders
Depression
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Psychiatric disorders
Hallucination
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Psychiatric disorders
Hallucination, visual
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Psychiatric disorders
Insomnia
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
23.8%
5/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.0%
4/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
12.5%
3/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Psychiatric disorders
Sleep disorder
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
9.5%
2/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
12.5%
3/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
11.5%
3/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Renal and urinary disorders
Pollakiuria
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
8.3%
2/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
40.0%
12/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
19.2%
5/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
15.0%
3/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
8.3%
2/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
11.5%
3/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
23.8%
5/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
12.5%
3/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.0%
2/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
8.3%
2/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
9.5%
2/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
2/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
12.5%
3/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
3/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
13.3%
4/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Respiratory, thoracic and mediastinal disorders
Sneezing
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Respiratory, thoracic and mediastinal disorders
Tachypnoea
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
8.3%
2/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Skin and subcutaneous tissue disorders
Erythema
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
3/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
8.3%
2/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
9.5%
2/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
3/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Vascular disorders
Haematoma
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
6.7%
2/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Vascular disorders
Hypertension
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
20.0%
6/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.7%
2/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
9.5%
2/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
15.0%
3/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
16.7%
4/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Vascular disorders
Hypotension
|
21.4%
3/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
13.3%
4/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
15.4%
4/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
3/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
25.0%
5/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Cardiac disorders
Tachyarrhythmia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Eye disorders
Conjunctival haemorrhage
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Eye disorders
Diplopia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Eye disorders
Periorbital oedema
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Oral disorder
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Paraesthesia oral
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Gastrointestinal disorders
Tongue haematoma
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
General disorders
Chest discomfort
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
General disorders
Chest pain
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
General disorders
Face oedema
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
General disorders
Facial pain
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Oral herpes
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Tinea pedis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Infections and infestations
Urinary tract infection enterococcal
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
8.3%
2/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
8.3%
2/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Injury, poisoning and procedural complications
Transfusion reaction
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
8.3%
2/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Investigations
Activated partial thromboplastin time prolonged
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Investigations
Prothrombin time prolonged
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
14.3%
2/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Metabolism and nutrition disorders
Hypernatraemia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Musculoskeletal and connective tissue disorders
Pain in jaw
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Nervous system disorders
Dysgraphia
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.8%
1/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Nervous system disorders
Somnolence
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
5.0%
1/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Psychiatric disorders
Agitation
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Psychiatric disorders
Irritability
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Psychiatric disorders
Tearfulness
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Reproductive system and breast disorders
Penile pain
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.3%
1/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
3.8%
1/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Skin and subcutaneous tissue disorders
Pain of skin
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
10.0%
1/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
|
Vascular disorders
Thrombosis
|
0.00%
0/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/30 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/26 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/21 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/20 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
7.1%
1/14 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
4.2%
1/24 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
0.00%
0/10 • Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until their study completion (up to approximately 61 months). SAEs and other AEs were assessed from first JCARH125 infusion until 90 days following the JCARH125 infusion (up to approximately 41 months).
The total number at risk for all-cause mortality represents all participants who underwent leukapheresis. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants that received at least 1 infusion of study medication (JCARH125).
|
Additional Information
Bristol-Myers Squibb Study Director
Bristol-Myers Squibb
Phone: 1-855-907-3286
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.
- Publication restrictions are in place
Restriction type: OTHER